CIK 0001676725 · Large accelerated filer
IDEAYA Biosciences, Inc.
Sign in to watch- Ticker
- IDYA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 474268251
- Phone
- 650-443-6209
- Business address
- 5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $985,397
- in 1 filing, $985K under 10b5-1 plans
Net −$985,397. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 67 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-06-01 | Throne Jason Chief Legal Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −3,553 | 62,905 | ||
| 2023-05-31 | Throne Jason Chief Legal Officer | Option exercise 10b5-1 | +432 | $7.01 | $3K | 432 |
| 2023-05-31 | Throne Jason Chief Legal Officer | Sale 10b5-1 | −432 | $23.00 | $10K | 0 |
| 2023-05-31 | Throne Jason Chief Legal Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −432 | 66,458 | ||
| 2023-05-22 | Throne Jason Chief Legal Officer | Option exercise 10b5-1 | +500 | $7.01 | $4K | 500 |
| 2023-05-22 | Throne Jason Chief Legal Officer | Sale 10b5-1 | −500 | $23.00 | $12K | 0 |
| 2023-05-22 | Throne Jason Chief Legal Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −500 | 66,890 | ||
| 2023-04-13 | Stone Paul A. Chief Financial Officer | Option exercise | +8,000 | $4.62 | $37K | 21,803 |
| 2023-04-13 | Stone Paul A. Chief Financial Officer | Option exercise · Stock Option (right to buy) | −8,000 | 129,832 | ||
| 2023-04-12 | Hata Yujiro S President and CEO | Option exercise | +11,601 | $4.31 | $50K | 677,887 |
| 2023-04-12 | Hata Yujiro S President and CEO | Option exercise · Stock Option (right to buy) | −11,601 | 474,454 | ||
| 2023-02-24 | WHITE MICHAEL ANTHONY Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +165,000 | 165,000 | ||
| 2023-02-24 | Beaupre Darrin Chief Medical Officer | Grant or award · Stock Option (right to buy) | +90,000 | 90,000 | ||
| 2023-02-24 | Stone Paul A. Chief Financial Officer | Grant or award · Stock Option (right to buy) | +140,000 | 140,000 | ||
| 2023-02-24 | Throne Jason Chief Legal Officer | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2023-02-24 | Hata Yujiro S President and CEO | Grant or award · Stock Option (right to buy) | +400,000 | 400,000 | ||
| 2022-06-09 | YARNO WENDY L Director | Grant or award · Stock Option (right to buy) | +11,000 | 11,000 | ||
| 2022-06-09 | SHANNON TIMOTHY M Director | Grant or award · Stock Option (right to buy) | +11,000 | 11,000 | ||
| 2022-06-09 | ROSEN TERRY J Director | Grant or award · Stock Option (right to buy) | +11,000 | 11,000 | ||
| 2022-06-09 | Kelley Susan L. Director | Grant or award · Stock Option (right to buy) | +11,000 | 11,000 |
Page 8 of 10 · 186 trades